This is a preprint.
Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries
- PMID: 34341787
- PMCID: PMC8328076
- DOI: 10.21203/rs.3.rs-745691/v1
Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries
Update in
-
Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries.BMC Med Ethics. 2022 Mar 9;23(1):21. doi: 10.1186/s12910-022-00764-1. BMC Med Ethics. 2022. PMID: 35264173 Free PMC article.
Abstract
Background In the pandemic time, many low- and middle-income countries are experiencing restricted access to COVID-19 vaccines. An access to imported vaccines or ways to produce them locally becomes the principal source of hope. But developing a strategy for success in obtaining and allocating vaccines is not easy task. The governments in those countries have faced difficult decision whether to accept or reject offers of vaccine diplomacy, weighing price and availability of COVID-19 vaccines against concerns over their efficacy and safety. Our aim was to analyze public opinion regarding the governmental strategies to obtain COVID-19 vaccines in three Central Asian countries, focusing particularly on possible ethical issues. Methods We searched opinions expressed either in Russian or in the respective national languages. We provided data of the debate within three countries, drawn from social media postings and other sources. The opinion data was not restricted by source and time. This allowed to collect a wide range of possible opinions that could be expressed regarding COVID-19 vaccine supply and public's participation in vaccine trials. We recognized ethical issues and possible questions concerning different ethical frameworks. We also considered additional information or scientific data, in the process of reasoning. Results As a result, public views on their respective government policies on COVID-19 vaccine supply ranged from strongly negative to slightly positive. We extracted most important issues from public debates, for our analysis. The first issue involved trade-offs between quantity, speed, price, freedom, efficacy and safety in the vaccines. The second set of issues arouse in connection with the request to site a randomized trial in one of countries (Uzbekistan). After considering additional evidences, we weighed individual with public risks and benefits to make specific judgements concerning every issue. Conclusions We believe that our analysis would be a helpful example of solving ethical issues that can rise concerning COVID-19 vaccine supply round the world. The public view can be highly critical, helping to spot such issues. An ignoring this view can lead to major problems, which in turn, can become a serious obstacle for the vaccine coverage and epidemics' control in the countries and regions.
Conflict of interest statement
Competing interests
The authors declare that they have no competing interests.
Similar articles
-
Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries.BMC Med Ethics. 2022 Mar 9;23(1):21. doi: 10.1186/s12910-022-00764-1. BMC Med Ethics. 2022. PMID: 35264173 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Concerns Expressed by Chinese Social Media Users During the COVID-19 Pandemic: Content Analysis of Sina Weibo Microblogging Data.J Med Internet Res. 2020 Nov 26;22(11):e22152. doi: 10.2196/22152. J Med Internet Res. 2020. PMID: 33151894 Free PMC article.
-
COVID-19 vaccines: concerns beyond protective efficacy and safety.Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5. Expert Rev Vaccines. 2021. PMID: 34180347 Review.
-
Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.Drugs R D. 2003;4(5):312-9. doi: 10.2165/00126839-200304050-00007. Drugs R D. 2003. PMID: 12952502 Review.
References
-
- WHO. Global equitable access to COVID-19 vaccines estimated to generate economic benefits of at least US$ 153 billion in 2020–21, and US$ 466 billion by 2025, in 10 major economies, according to new report by the Eurasia Group. 3 Dec 2020. https://www.who.int/news/item/03-12-2020-global-access-to-covid-19-vacci.... Accessed 3 March 2021.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials